TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05642832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Throughflow titration phase
Description: Ventilation will be applied in the TF mode with TF set to 0 LPM for 10 minutes. Patients will receive assist through the NAVA line of the tri-piece (NAVA set to similar settings as Servo period, \~60-80 LPM flow). Ventilation with Throughflow will be started at a TF flow of 5 LPM, and the NAVA flow will be reduced by 5 LPM. After 10 minutes measurements will be collected. If Edi is greater than or equal to 4 µV, TF flow will be increased to 10 LPM and NAVA flow will be adjusted to keep total flow constant. Measurements will be collected again after 10 minutes. TF flow will be increased in steps of 5 LPM and measurements collected every 10 minutes until Edi is below 3 µV or TF flow reaches the total flow observed during the NAVA period.~After either the Edi target has been met or TF flow has reached the total flow, ventilation with TF will be reduced in steps of 5 LPM every 10 minutes (the reverse of the above), while NAVA flow is accordingly adjusted to keep total flow constant.
Study: NCT04644172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instrumental Activities of Daily Living Shaping
Description: In addition to training on the SOPT software, participants will train on tasks that simulate everyday activities that have important cognitive components (e.g., selecting medicine bottles from a cabinet, measuring ingredients to bake a cake, finding information online). The training will follow shaping principles. Activity periods will be divided into trials of specific length, and the performance of the participant will be measured and graphed to provide the participant with feedback on their performance. Verbal praise will be used to reward a participant for improvements in performance. The difficulty of the task will be increased in small increments as a participant gains mastery. The purpose of this component is to serve as a bridge between the SOPT training, which exercises a basic aspect of cognitiven function, and cognitive function in everyday life, which is embedded in the context of multi-part, and multidimensional tasks.
Study: NCT06055608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Participants in Group 1 will transition to sirolimus therapy on day 14 (+/- 5 days) - weight \<40 kg will receive 3mg/m\^ 2, with maintenance dose of 1 mg/m\^2 divided BID - weight \>= 40kg will receive 6mg/m\^ 2, with maintenance dose of 2 mg daily
Study: NCT04644172

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Transfer Package from CI Therapy
Description: Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transfer Package from CI Therapy
Description: Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Healthcare that is available for adults with cognitive impairment subsequent to COVID-19 in the community on a clinical basis. This includes commercially available, gamified, computerized cognitive training programs.
Study: NCT06055608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept will be administered as an intravenous infusion over 30 minutes. The belatacept dose for the study is 10 mg/kg on post-operative day (POD) 1, 5, 14, 28, 56, 84 for the first 3 months, followed by 5 mg/kg every 4 weeks (+/-4 days), starting on month 4 until month 24
Study: NCT06213987

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.025% Tretinoin
Description: Total duration of 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.025% Tretinoin
Description: Total duration of 8 weeks.
Study: NCT06055608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil-MMF will be initiated at 600 mg/m\^2 BID until tacrolimus is at therapeutic levels, then 450 mg/m\^2 BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Group1)
Description: Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels. Participants in Group 1 will be transitioned to sirolimus 2-4 weeks post-transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin (ATG)
Description: Participants will receive induction therapy with anti-thymocyte globulin (1.5 mg/kg/dose, maximum 125 mg) starting intraoperatively on day 0 and continuing on days 2 and 3 (total dose 4.5 mg/kg). Total dose may be extended to 6 mg/kg over 1-2 days for delayed graft function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin (ATG)
Description: Participants will receive induction therapy with anti-thymocyte globulin (1.5 mg/kg/dose, maximum 125 mg) starting intraoperatively on day 0 and continuing on days 2 and 3 (total dose 4.5 mg/kg). Total dose may be extended to 6 mg/kg over 1-2 days for delayed graft function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (Group 2)
Description: Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels
Study: NCT06515613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTIM-76
Description: Claudin 6 bispecific Antibody administered weekly (Day 1, 8, 15 and 22) of a 28 day treatment cycle until disease progression.
Study: NCT06144970

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TG-C High Dose
Description: High Dose - 1 mL of the combined TG-C cells
Study: NCT06403657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An enhanced model of hepatitis B testing and linkage to care
Description: Implementing CME sessions (\<50 attendees) at Le Van Thinh Hospital will focus on preventive strategies for hepatitis B (HBV). We'll collaborate with IT to integrate a Best Practice Advisory (BPA) system into the hospital's electronic records for hepatitis B testing reminders. The system prompts healthcare workers when a patient lacks HBV screening notes, ensuring timely education and testing. Also, we'll introduce Point-of-Care (POC) HBsAg testing using SD Bioline HBsAg WB® for efficient screening and counseling, with follow-up to ensure care linkage within two weeks.
Study: NCT06144970

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TG-C Mid Dose
Description: Middle Dose - A volume of 2 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TG-C Low Dose
Description: Low Dose - A volume of 9 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Single subcutaneous injection of normal saline
Study: NCT06654102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep UVA Irradiation
Description: A timed series of 6 UV doses will be administered to subsites 2 to 7 within Test Site 1 and 2 using an accurately calibrated solar simulator by varying the irradiation intensity for each subsite and keeping the duration of irradiation constant for all subsites. The duration of irradiation for each test site will be 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep UVA+HEV Blue Light Irradiation
Description: A timed series of 6 UV doses will be administered to subsites 2 to 7 within Test Site 3 and 4 using an accurately calibrated solar simulator by varying the irradiation intensity for each subsite and keeping the duration of irradiation constant for all subsites. The duration of irradiation for each test site will be 30 minutes.
Study: NCT06391424

Intervention type: DIAGNOSTIC_TEST
Intervention: Spontaneous Breathing Trial
Description: Patients will undergo an SBT to determine whether they are ready for extubation.
Study: NCT06515756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post operative pain assessment after root canal treatment
Description: the sealer was administered to the root canal using the initial paper point and then uniformly distributed using a second paper point before removing any excess sealer with a third paper point. Once the sealer was applied, a single tapered gutta-percha cone was adjusted to fit the root canal. The coronal access cavities were restored with a composite resin material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post operative pain assessment after root canal treatment
Description: the sealer was administered to the root canal using the initial paper point and then uniformly distributed using a second paper point before removing any excess sealer with a third paper point. Once the sealer was applied, a single tapered gutta-percha cone was adjusted to fit the root canal. The coronal access cavities were restored with a composite resin material
Study: NCT04781257

Intervention type: DIAGNOSTIC_TEST
Intervention: New test candidates
Description: The following new diagnostic tests will be done after the completion of the study with the samples (blood, sputum, urine) and data (digital X-ray) obtained during the study period:~CAD4TB / qXR Xpert Ultra® FLOW-TB TAM-TB 4RISK and COR Cepheid 3-gene signature cartridge BioMérieux ISIT TB blood transcription signature assay Multiplex LSHTM in-house host biomarker assay TB Screen biosignature SeroSelect~Retrospective testing of participants' samples and data acquired during the study period, differentiated between participants with co-prevalent/incipient TB and participants staying health throughout the trial

Intervention type: DIAGNOSTIC_TEST
Intervention: New test candidates
Description: The following new diagnostic tests will be done after the completion of the study with the samples (blood, sputum, urine) and data (digital X-ray) obtained during the study period:~CAD4TB / qXR Xpert Ultra® FLOW-TB TAM-TB 4RISK and COR Cepheid 3-gene signature cartridge BioMérieux ISIT TB blood transcription signature assay Multiplex LSHTM in-house host biomarker assay TB Screen biosignature SeroSelect~Retrospective testing of participants' samples and data acquired during the study period, differentiated between participants with co-prevalent/incipient TB and participants staying health throughout the trial
Study: NCT05203068

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Recombinant tuberculosis allergen (RTA)
Description: Single intradermal application of 0.2 µg/0.1 mL RTA (CFP10-ESAT6) in the middle of the forearm
Study: NCT03520751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: scAAV1.tMCK.NTF3
Description: gene vector
Study: NCT06598436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Health Coaching (Patient-Level Intervention)
Description: The patient-level intervention combines the role of digital health navigator and chronic disease health coach to facilitate access to devices and broadband, offer digital skills training, and provide chronic disease health coaching focused on telehealth modalities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Health Coaching (Patient-Level Intervention)
Description: The patient-level intervention combines the role of digital health navigator and chronic disease health coach to facilitate access to devices and broadband, offer digital skills training, and provide chronic disease health coaching focused on telehealth modalities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (Clinic-Level Intervention)
Description: The clinic-level intervention includes primary care clinic support through practice facilitation that empowers team members to address racial/ethnic disparities in telehealth use through consistent review of telehealth equity data and input from clinic-specific Patient Advisory Councils (PACs).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (Clinic-Level Intervention)
Description: The clinic-level intervention includes primary care clinic support through practice facilitation that empowers team members to address racial/ethnic disparities in telehealth use through consistent review of telehealth equity data and input from clinic-specific Patient Advisory Councils (PACs).
Study: NCT06609525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO0303-A
Description: eye drop, 1 drop 3 times (every 5 minutes) a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTO0303-B
Description: eye drop, 1 drop 3 times (every 5 minutes) a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTO0303-C
Description: eye drop, 1 drop 3 times (every 5 minutes) a day
Study: NCT06611007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: embolization therapy
Description: Hand arterial embolization with Lipiodol in emulsion with iodinated contrast agent
Study: NCT06616597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000mg/ day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000mg/ day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 0.5mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 0.5mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 1500mg/ per day
Study: NCT05540470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PART
Description: Chloroquine(150mgs tablets) weight-adjusted dosage ; An 8-aminoquinoline drug~1. Primaquine (PQ) (15 mg tablets): weight-adjusted dosage. (Rationale: this short-course posology has been chosen to facilitate the adherence to treatment for asymptomatic individuals participating to the Module A, Primaquine will be administered to all participants to Module A during the induction phase of the intervention.~2. OR tafenoquine (TQ) (150 mg tablets): 2 tablets as a single dose (orally), (Rationale: the posology chosen corresponds to that used in phase III trials for the radical cure of P. vivax and the therapeutic recommendation in Brazil). Tafenoquine will only be administered during the full implementation phase to participants who do not meet exclusion criteria.

Intervention type: DRUG
Group type: OTHER
Intervention: Malakit
Description: delivery of a sturdy, lightweight, waterproof plastic involucre that contains:~* 1 laminated sheet with illustrated instruction~* 1 complete anti-malarial treatment targeting P. falciparum, but also effective in acute forms of P. vivax with association with artemisinin derivatives~  * A blister of 24 tablets of Artemether 20 mg + lumefantrine 120 mg of generic medication~ * Two 15 mg tablets of primaquine, to be given as a single dose (145)~* 1 symptomatic treatment (analgesic, antipyretic): a blister pack of 10 paracetamol 500 mg tablets~* 3 Malaria rapid diagnostic tests (RDTs) in individual packs and with easy-to-use retractable lancets. Three tests will be included, taking into account the possibility of having one or two negative or invalid tests before returning to a distribution site for further supplies.

Intervention type: OTHER
Group type: OTHER
Intervention: CROSS-SECTIONAL PRE- AND POST-INTERVENTION SURVEYS
Description: Surveys will include the collection of a detailed questionnaire on recent malaria and mobility history, a clinical examination, and a venous blood sample

Intervention type: OTHER
Group type: OTHER
Intervention: QUALITATIVE STUDY
Description: Systematic mapping of stakeholders in the pre-intervention period Semi-structured interviews and focus groups. Observational techniques Participatory approach. Participatory design of a community-based adverse event surveillance system
Study: NCT05460832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS2320 5 mg
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS2320 20 mg
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS2320 40 mg
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT06610604

Intervention type: PROCEDURE
Intervention: thermal ablation
Description: thermal ablation including microwave ablation, radiofrequency ablation of thyroid nodules

Intervention type: PROCEDURE
Intervention: thyroidectomy
Description: surgical resection of thyroid nodules
Study: NCT05553522

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
Description: SRS and oral tucatinib for 2 wk, followed by oral tucatinib, oral capecitabine, and intravenous (IV) trastuzumab maintenance during 21-d cycles until tumor progression, participant withdrawal, a severe adverse event deemed related to the study drug, or the treating physician discontinues the drug. There are three dosing levels of tucatinib (Dose Level 0, Dose Level -1, or Dose Level -2) using a dose de-escalation scheme. Dosing of capectabine (1000 mg/m2 BID Days 1-14) and trastuzumab (6 mg/kg once per 21 days; 8 mg/kg initial loading dose) per cycle will remain the same regardless of tucatinib dosing.~Dose Level 0: 300 mg twice a day (BID) continuously for 2 wk post SRS, then 300 mg BID continuously per cycle.~Dose Level -1: 250 mg twice a day (BID) continuously for 2 wk post SRS, then 250 mg BID continuously per cycle.~Dose Level -2: 200 mg twice a day (BID) continuously for 2 wk post SRS, then 200 mg BID continuously per cycle.
Study: NCT06682039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Engage in ABM + gratitude/savoring sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Engage in inert attention task sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive and respond to text messages to complete gratitude/savoring activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text Message-Based Navigation Intervention
Description: Receive and respond to mood text messaging prompts
Study: NCT06118099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Injection solution SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection solution SC injection
Study: NCT06708572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: 20 patients will receive subcutaneous GCSF at a daily dose of 10ug/kg for 3 consecutive days. It is administered within 3-4 days after the Kasai procedure.
Study: NCT06723197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan+amoxicillin
Description: Drug combinations for dual regimens：vonoprazan+amoxicillin
Study: NCT06003036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham stimulation
Description: sham delivery of transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham stimulation
Description: sham delivery of transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: accelerated intermittent theta burst stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: accelerated intermittent theta burst stimulation
Study: NCT06723197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vonoprazan+amoxicillin
Description: Drug combinations for dual regimens：vonoprazan+amoxicillin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of eradication regimen: 7-day
Description: Duration of eradication regimen: 7-day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan+amoxicillin+tetracycline+bismuth
Description: Drug combinations for quadruple regimens: vonoprazan+amoxicillin+tetracycline+bismuth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of eradication regimen: 10-day
Description: Duration of eradication regimen: 10-day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Duration of eradication regimen: 14-day
Description: Duration of eradication regimen: 14-day
Study: NCT06717672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% without vessel constrictor
Description: 1. _Lidocaine 2% provides rapid and effective local anesthesia for minor surgical procedures, such as biopsies, excisions, and suturing.~2. _Pain relief_: Lidocaine 2% has been shown to provide significant pain relief in patients with acute pain, such as post-operative pain, trauma, and burns.~3. _Reducing pain intensity_: Lidocaine 2% has been shown to reduce pain intensity by 30-50% in various clinical studies.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline used is an iv fluid given for fluid replacement